Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

CHS-0214

Other · developed by Coherus Oncology

Phase 3 Most advanced trial (none active)
CHRS Developer
1 Registered trials

What is CHS-0214?

CHS-0214 is a drug studied in plaque psoriasis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Dermatology
Developer
Coherus Oncology, Inc. (CHRS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02134210 Phase 3 Plaque Psoriasis Completed CHRS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Plaque Psoriasis

More from Coherus Oncology

Toripalimab FDA approved Casdozokitug Phase 2 CHS-1000 Phase 1 Perenostobart Phase 2 Tagmokitug Phase 1

Follow CHRS, the company behind CHS-0214

See CHRS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CHRS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.